Q4 2019 Earnings Call
Thank you. And thanks everyone on the phone for joining us today. Let's quickly review the topics we will cover today. I'll begin with a brief summary of our 2019 company highlights before turning the call over to age. Well harradine our CFO follow take us to the fourth quarter and full-year financial results and provide our 2020 guidance. Then review the segment highlights and catalysts before opening the line for a question beginning on slide for in 2019 are singing was pivot to office or focus on driving organic growth in our core businesses. We have now delivered eight consecutive quarters of organic growth and 2019 was our first full year of reported Revenue growth since 2015 grew organically by 4% in 2019 reported revenues were up 3% Our largest segment B&L International delivered its third consecutive year of mid single-digit organic Revenue growth sales rep.
pretty full year Revenue
More than two billion dollars for the first time ever. We generated one point five billion of cash from operations. We increased R&D investment by 14% compared to 2018 and we used approximately 1.1 billion dollars of cash to pay down roughly $900 of debt and fund approximately $250 of bolt-on Acquisitions or license and products pivoting to offense also include launching new products and driving their growth and our new products continue to grow first following the launch of Thermage flx and asia-pacific the Thermage franchise sauce 73% organic Revenue growth compared to 2018 this exceptional growth rate of made the Thermage one of the baohaus top ten franchises in 2019. Lumify achieved a weekly market share of approximately 43% Mm. Yep.
18 is number one.
Recommended product in the redness reliever category truly empty rx's grew by 31% year-over-year and we have improved the market access position for approximately thirty five million lives since we acquired the product in the first quarter of 2019, you will has been another standout weekly trxs grew by 25% from the 3rd to the 4th quarter of 2019, and we have now achieved 63% commercial access.
Overall the entire bombshell team of twenty two thousand employees delivered on a promise to Pivot to offense in 2019 and demonstrated the durability of our business, which we grew both organically and through strategic bolt-on Acquisitions great effort by the entire bio. She'll theme balls going to walk you through the fourth quarter and full-year results in more detail. So with that I'll turn it over to Paul. Thanks, Joe will lot to cover. I'll try to go fast good quarter and a Goodyear a little different approach this quarter. I'm going to start with slide five a summary of the changes in Revenue by segment in major business unit fought for and a full year 2019 all then walk down the top-level piano for the quarter and provide some observations about the full year before turning to our guides for 2020 quick reminder when we talked about on a growth that means excluding the impact of changes in the FX rates the impact of divested and discontinued businesses in the prior-year periods, and the impact of acquired businesses. Okay Slide Five in the quarter we posted. Yep.
percent organic Revenue growth versus Q4
2018 recall that last year we took steps to reduce our Channel inventories held at wholesalers in that that had the effect of reducing Q4 Revenue by an estimated 76 million dollars. So, that's a Tailwind for us this quarter excluding the impact of the inventory contraction. We still posted top-level organic Revenue growth of plus 1% There were a lot of moving Parts but a lot of good stuff within each of our segments. Let's start with salek said it was the largest contributor organic Revenue growth in the quarter up 17% organically on continued strong performance from xifaxan up 29% relative or up 29% in Plainview also contributed growth. We lost exclusivity for appraisal in the Florida and that combined with the continued generic erosion of uceris offset some of the growth not a factor in organic growth truly in sales told eighteen million in the quarter and fill TRX is were up 69% versus Q4 of 18 a strong quarter from Salix to wrap up a grass.
year posting 13% or
And revenue growth for the full year versus 2018 despite aloise B&L International segment. Revenue was up 3% organically in the quarter led by global consumer plus 7% organically off Sprint the lumify in the us and our Global contact lens solution Brands renew and Biotrue Multi-Purpose Global surgical was plus 5% organically in the quarter on strengthening consumables for the back of the eye and investor, iol's Global Vision Care was plus 4% organically in 1/4 on strength in Ultra monthly silicone hydrogel lenses are alcoholics daily life lenses in Japan and Biotrue oneday lenses are in the National Farm of business was essentially flat versus Q4 of 18 while Global also RX declined 2% organically as grown by Zelda and prolensa will more than offset by the decline of the lotemax Brand family due to generic erosion for the full year being L International grew 5% organically consistent with birth.
believe that this diverse and durable
Segment can deliver mid single-digit growth over time all five of the international business units posted organic Revenue growth for the year led by global consumer up 6% organically on strengthen lumify in the us and our our vitamins globally followed by Global Vision Care up 7% organically with contributions from our Biotrue oneday lenses monthly Ultra lenses and our our clocks daily side Highlands in Japan are in National Farm of business was up 5% organically on strength in Russia Egypt and Canada Global optimum Rx was up 2% organically unlike in the quarter for the full year growth of Ulta prolensa and a portfolio of our International ophthalmic Brands overcame the yellow we drag from lotemax home. You also German illogic segment declined 1% organically in Q4 of 19 verses eighteen a spectacular growth in our Global Aesthetics business solta which is up forty 2% nearly overcame.
18% decline in
Nickel Dermatology in this world of business. The Thermage platform is now solidly in the top ten products for the entire company and was a significant contributed a company-wide growth Eloise plays a big role in the quarterly decline in medical Durham. Mainly Scream, the ballots are promoted products in the medical in medical Durham including do ovary Julia and Sallie Mae kru versus Q4 2018. It's pretty much the same story for the ordering segment for the full year strong growth from Global salt + 45% organically for the year more than offset by the decline in medical technology for the four-year medical term was our business most impacted by Eloise a minus $121 grow Drag versus 2018 on the plus side Juliet was one of the top fifteen contributors to company-wide revenue growth in 2019 versus eighteen as the impact of Eloise moderate in this segment Juliet together with Our Brands and growth phase. That's due or briefing.
Holly form the
Or of our medical during portfolio in the basis for an expected return to growth in this business in 2020. Finally the Diversified segment, which declined 5% organically in the quarter as Eloise offer a $29 million-dollar drag on the neuro business are generics business grew 3% organically in the quarter with authorized generic versions of our branded products that lost exclusivity. Mainly use Cyrus a price low to Max & L edel providing the bulk of that growth for the full-year Diversified declined 5% organically as 11% growth of our generics business offset some of the 116 million Dragon our normal business total company revenue for the year grew 4% organically with 2% coming from improved realized net selling prices and 2% from increased volume would flip the slide six the p&l summary for the quarter our gross. Margin. The quarter was 71.4% down about twenty basis points versus Q4 2018 mainly due to higher inventory write-offs. And yep.
or nineteen relative to the prior-year
Order note that for the full year. Our gross margin was 72.7% favorable by 80 basis points versus 2018 with mix a Big Driver particularly impact of the growth of xifaxan wage, but also from improvements associated with our project core activities are final guidance for the full year for gross. Margin was roughly 73% selling a an advertising wage expenses in the quarter. We're up or unfavorable on a constant currency basis by 6% versus Q4, 2018 due to the addition of trulance the Salix portfolio and higher costs and Vision Care to support new launches and an international Farmer for product launches particularly in Canada in Russia adjusted G&A expenses on a constant currency basis 8% unfavorable order compared to Q4 of 18 due to increased costs of Business Development initiatives and higher ongoing it costs as we continue to work to improve our Global operating systems wage.
I want to point out that in Q4 2819 adjusted GNA run rate is it's above what I would expect on average the quarterly run-rate to be in 2020 the go forward adjust. The long run rate is likely between the $163 million. We saw on Q4 and the 140 million average over the first three quarters of 2019 R&D was down in the corner of favorable light 5% on a constant currency basis. I would not read much into that as just how the timing of expenses fell in both. For the full year. R&D was up 15% on a constant currency basis. 471 million slightly below our final 2019 guidance for R&D of 480 million again, just the timing of how expensive spell as you'll see when I get to twenty twenty guidance. We intend wage bit more Capital to R&D activities adjusted ebitda in the quarter was $898 Million up 5% from the year-ago quarter on a constant currency basis a solid quarter than enabled us to post office.
Custody but of three.
Point five seven $1 billion for the full year, which was plus 4% on a constant currency basis from 2018 and just below the top end of our final guidance range for 29% off flight seven. I think it's more taking a look back at how we did in 2019 relative to the midpoint of our original 2019 guidance, which was eight point four billion of Revenue and 3.425 billion of adjust the dbap our actual 2019. Revenue was on was 201 million above the midpoint of original Guidance with a favorable result a function of four things. The acquisition of true Lance added $55 billion revenue from a Louis assets was plus $53 million are based business was favorable by 115 million and are setting the good guys changes in FX rates reduced Revenue by summer two million dollars adjusted ebitda was $146 Million above the midpoint of our original guidance FX had no impact trulance had no impact the venturella. We're Avenues a dog.
36 million a profit the
At a base performance at seventy 1 million in profit while investment in R&D in sg&a spending were both a bit above our original view the biggest single factor in the improved adjusted ebitda. Jeff gross margin coming in a hundred twenty basis points better than initially forecast which accounted for roughly one hundred million dollars of lift point in the story. Is that as the year played out? We have some good fortune a l o e assets but the Lion's Share of the better results came from our commercial units driving improved performance in our base businesses from our project core activities to improve gross the Nets and Thursday are Relentless efforts to improve efficiency in our supply chain a Goodyear turn to slide eight the cash flow summary our net cash provided by operating activities in 2019 came in at one point five zero 1 billion the low end of our expected range as we increased inventories of certain free products and API to ensure uninterrupted Supply note that at your end. We have three point two for 4 a.m.
You know cash on hand.
As we completed an offering of two point five billion of unsecured notes in late December and had not yet applied those proceeds to the payment of the US Securities litigation that's 1.21 billion and the prepayment of other debt totaling 1.24 billion net of those amounts and related fees are working cash at your end was roughly 750 million similarly on slide 9 to cash and debt on a balance sheet, you're under inflated due to the timing of the two point five billion dollar debt raised and the use of those net proceeds. I think of it like this pro forma for the deployment of those funds our net debt at year-end would have been a roughly 24.2 billion settling the US Securities case status back in our progress reducing the Quantum of our debt and improving our leverage ratios, but it was absolutely the right thing to do to quantify life in steadily significant over any uncertainty a quick aside just last week. We began the process of calling another 100 million principal amount of bonds. We intend to continue to systematically grind. Yep.
It down one last.
Hang on the balance sheet during the quarter we accrued for the settlement of the u.s. Stock dropped case other related cases and ongoing letting Legacy litigation and investigations. The total accrual was a check for 1.39 billion is and is included in gap other income and expenses in our p&l for the avoidance of doubt. We exclude this expense from the computation of adjusted ebitda manage that income finally and onto the money slides for me starting with slide ten showing our guidance for 2020 our Revenue guidance for 2020 is a range of 8.65 to 8.85 billion and that represents a range of growth of plus 1% The plus 3% at current FX rates are adjusted ebitda guidance is a range of 3.5 to 3.65 billion representing a range of minus 2% 2 + 2% at current rates. I want to cover the other elements of our guidance on this slide before talking about how to think about those revenue and profit growth rates for 12 a.m.
I just
Sg&a expenses were two point five billion in 2019 and were guided to approximately 2.6 billion for 20 20 the roughly one hundred million or 4% increase is higher than it may as we look ahead to twenty twenty one and twenty twenty-two in our twenty-twenty plan. We rationalized off X across several business units, but we also allocate incremental selling advertising personal resources to some units to support launched products and products and launch basis including daily cyhi lenses lumify to overeat and Thermage in G&A. We're continuing check out our Global it organization and infrastructure in that comes at a cost increasing our adjusted GNA in 2020 vs 2019 as we move forward into twenty twenty one and twenty twenty two. Am we should be able to hold the growth of sg&a below that of Revenue growth. We're guiding to roughly five hundred million in R&D for 2020 up roughly $30 million from 2019.
2017 our investment in R&D total 361 million over the last few years, we built up the R&D organization and infrastructure to support an increase volume of product to sustain each of our home businesses that includes reducing the investment intensity in some areas while increasing commitments to other areas where we had been underinvested over over a number of years and that's specifically why am I being a surgical and also RX while a 6% increase in R&D reduces our near-term earnings and earnings growth? It's the right thing to do to enhance our prospects to deliver long-term organic Throat for interest expense regarding to 1.55 billion down from 1.6 billion, despite the addition of 1.21 billion of debt to fund the settlement of the US Securities class-action. Our tax rate on adjusted earnings was 7.8% in 2019. We expect that rate to be about the same roughly 8% in 20 20 towards the bottom of the page note that we're guiding to age.
if you go back to
expenditures in 2020 of roughly three
In the past I said that our steady-state capex might be roughly 160 275 million per year and the uptick in 2019 was mainly due to investments in connection with the daily wage hydrogel lands initiative and are billed out of our Global it systems over time. We've determined that underinvestment particularly in our supply chain over the last number of years status necessitates increased investment in 2020 and Beyond it's our current view that after roughly three hundred million of investment in 2020. We will likely see capex requirements decrease in 2021. And again in 2022 our steady-state a few years out maybe closer to two hundred twenty five million of capex per year continue consideration my license and license agreements total 58 million 2019, and we're guiding to roughly one hundred million in 2020. The increase is related to a forecast sales Milestone on relistor and payments.
related to the recently acquired rights desire.
and Novo three
finally restructuring in other in 2019 these items total 52 million and 2020 were guiding 275 million point out that this site and represents our estimate of restructuring costs some systems integration with them in a legal cases and investigations turning the site eleven the bridge from 2019 actual results to our 2020 guidance first focus on the yellow impact, we're forecasting a $275 million dollars of growth drag from the basket of a Louis assets and twenty20. The good news here is that we have finally finally close to putting the impact of the large bucket of Eloise behind us in 27 vs. 16 the growth drag was four hundred eighty six million in 18 verses Seventeen. It was $289 million in nineteen versus eighteen. It was three hundred and sixty Million Dead last three years. Our Revenue growth was trampled by more than 1.1 billion of Lala. We Dragged In twenty-twenty. We expected dragged a moderate the 275 million and here's the good part. That's birth.
unless realizing revenues on the
Louis basket of $237 billion in 2020 and while that amount will decline into 2021 vs. 2022 drag will be substantially reduced. We did not add any new, LOL Holloween basket and twenty twenty and looking out over the period from 21 to 23. We expect the impact of future l o e assets to be quite manageable the Bass Performance of + 100, excuse me, $315 million is impacted in negative ways by a few things that I called out on our last call and a few others worth noting first. There's the non-recurring portion of the improvements and gross the Nets that we saw in 2019 and especially in Q3 that are a headwind to 2020 Grove next. The trajectory of is the trajectory of glumetza. Will Masa had been a strong performer through the first three quarters of 2019 before as we forewarned. It dropped almost in half in Q4 in his now expected to Trend downward from the air in future quarters next and one I had known no,
Previously called out for you.
We had terrific performance in our genetics business in 2019 with major contributions from the authorized generic versions of uceris and Elidel as more generic versions of these prize have launched. We will see something begin to clients and revenue for our a GS and twenty twenty think of the a Jesus us stretching the tail of brands that lose exclusivity. It's good, but it's fleeting one other bit of color. The base package would have been better, but our guidance includes an estimate of a meaningful headwind for on our asia-pac region, especially China associated with the coronavirus situation. Our Revenue guidance includes a roughly fifty million dollar coronavirus impact that's an estimate and we'll see how this plays out over twenty twenty. Obviously this impacted our adjusted ebitda guidance as well. So these items part of the reason why the revenue growth in 2020 implied by Guidance is only in the range of 1% to 3% at current F x-rays turning the ebitda bridge at the bottom of the page the currency. Yep.
In R&D impacts are self-explanatory.
Within the Bass Performance. We're absorbing the roughly one hundred million or 4% increase in sg&a and a coronavirus impact on our Revenue expectations impacts our adjusted ebitda. Well all these items together our drivers of the adjusted ebitda growth rates supplied by our guidance ranges being below that of our Revenue growth rate. That's it for me. That's U Joe. Thank you Paul on slide 12, there's a lot of information but the important message to highlight is we have now delivered three consecutive years of mid-single Digit organic Revenue growth for being a national Lionel International was up 6% in 2017 up 4% in 2018 and up 5% in 2019.
Turning to slide thirteen Global Vision Care has been a strong performer. And I want to highlight two products that have been key drivers of the growth in this business Biotrue oneday and Ultra contact lenses dead Michonne five-year reported revenue for each and the charge from the bottom of slide 13 on the left from 2015 through 2019 Biotrue oneday lenses had a 22% compound annual growth rate in organic Revenue grew by 23% in 2019 on the right Ultra lenses had a 32% over the past five years and grow organically by 24% in 2019. We've called out the significant Milestones that drove incremental growth including the launches of lenses for astigmatism presbyopia and extended. We're this strong performance underscores the durability of these products in the strength of the Bausch & Lomb brand.
We're seeing.
Increase market share in u.s. Vision cure this business gained 1.6 SharePoint to 11% unit share for the month of December 2019 versus a 9.54% share in December 2018. Finally, we plan to launch our daily silicone hydrogel lenses in the US later this year silicone hydrogel lenses are one of our fastest-growing segments of the content and Market.
Starting to slide 14th for an update on global consumer. I want to highlight two franchises first our top-selling I vitamin portfolio in the US occupied and preservation do organically by 4 per month 2019 and had a kegger about 7% from 2015 to 2019 and second lumify the number one physician recommended product and the redness really ra-kang had sales of $63 million in 2019 and achieved a weekly market share of approximately 43% and slide fifteen. We highlighted and Vistas performance package Global surgical business in Vista family intraocular lenses are are clear artificial lenses that eye surgeons used to replace a person's natural lenses when it becomes too cloudy dog cataract in Vista grew organically by 36% 2019 the chart below provides invested reported revenue for the past five years, which grew at a 22% Kanger.
We also launched in.
The torque in 2019 which was shown in the bottom, right?
Looking ahead to the 2020 Cadillac we expect to launch it extended depth of focus intraocular lens platform in 2020 with the introduction of this platform. We will be entering the premium package will segment outside the US and finally we expect to launch a pre-loaded iol injector platform for in Vista and the second quarter of 2020.
Movie now to slide sixteen before we go to the key highlights for Salix. I want to address to updates first after reviewing our GI portfolio light of Market opportunities. We decided to increase promotional focus on facts and and true Lance and a discontinued promoting. And lucemyra
Also, we recently received notice that Norwich Pharmaceuticals have filed an A and ETA for a fax them in five hundred eighty milligram tablet Alpha Sigma and bowels will file suit against Norwich alleging patent-infringement and will trigger 8:30 months day of approval. We remain confident in the strength of the twenty-three patents covering by fax and we will continue to vigorously defend our Vital actual property the chart of the right shows that faxes T-Rex growth over the past nine quarters, as you can see trxs grew by 7% of 2017-2018 off 8% from 2018 to 2019 for ibs-d specifically T-Rexes grew by 15% in 2019 compared to eighteen moving out faster here exes grew by 6% in 2019 in the beginning in twenty-twenty. We recently improved relistor World Market access position for more than fifty million lived.
only truly is
TRX is groove by greater than 30% in 2019 and since the acquisition we have improved the market access position for approximately $35 million lives. We are seeing progress in a brand in Market or trillions new RX market share grew by from 3.9% to 6.4% in 2019 Honda side 17-6. First you over to your exes were up 25% in the fourth quarter compared to the third quarter and we're very pleased with this launch as we show in the chart on the bottom left with them to quarters of launch is capturing approximately 40% of new patients who are started on a first-line branded topical or oral psoriasis product. When you look at do over get these three competitors listed, we believe it gives a perspective on the opportunity for do ovary and the potential savings that could result from delaying the need to start patients on a biologic.
Also, I'm delighted to.
Say that do ovaries now at 63% commercial access for the United States and we gain as we gain incremental coverage, we expect reduced couponing support and expect them will improve over time importantly average selling price increase from the third quarter and we ended the year with a higher ASP. We are clearly moving in the right direction. We are very enthusiastic about the opportunity for do ovary primarily because for the first time we can authorize his face as a topical product with high-potency corticosteroid that they can treat to clarify rather than being led to a certain duration of time moving now to sleep trxs grew by 100% in 2019 compared to the prior-year and we achieved 67% commercial access.
We hardly hear X is 60% in the second half of 2019 compared to the first step would be highly now has 71% commercial access We Believe access rates of sixty to seventy percent divorce rate that Managed Care recognizes the value in the efficacy of our psoriasis products and helping to improve patients lives on the right. We hired a new cat spay model for a prescription Dermatology products in the United States. That's now available online at Dermatology telemedicine are available on the platform. As of yesterday. Iconic wage has written a will be available on Dermatology, as well as new products like Al Pacino. The platform was launched with a portfolio of 15 products and we plan to expand the number of cash pay products over time. We believe that Dermatology has the potential to meet patient needs and help grow our Dermatology business.
turning
To slide 18 or Aesthetics business Global sort of grew organically by 42% in the fourth quarter 2019 versus the fourth quarter of 2018 and 45% in the full given by the global expansion of Thermage flx. Thermage is a non-invasive radiofrequency therapy that can address the signs of aging skin. You can see that Trend in the charging the left like 46% kegger from 2017.
Looking at the 2020 Beyond we expect to see continued Global expansion for Thermage flx, including Geographic expansion in the U and slide nineteen. You can see we have a good phone number of late-stage development programs in each of our four business segments. We increased our investment 2019 versus 2018 and allocated a greater percentage of R&D budget divorce. Is Felix on a full year basis.
Watching new products will drive our future growth. We are pleased to have active late-stage pipeline Innovative new programs with potential expand our Eye Health GI and dermatology portfolio.
I talked about the some of the programs along the way but I want to highlight a couple of them in more detail.
Before we turn to slide twenty at the beginning of 2018. We identified the significant seven as key drivers of future growth and these seven products group collectively by 68% off 2019.
Well, we are pleased with that growth limiting ourselves to seven products and excluding growth products like Biotrue Ultra preservision Thermage a pleasant long as I fax. It doesn't give a complete picture of the expected drivers of our future Revenue growth accordingly. We will continue to report revenue for our top 10 product for each business with an overall for about help but with no longer report combined revenue for the significant seven. Let's turn to slide twenty-four additional detail are promising late-stage programs and g i and I health
It was Salman is a late-stage oil, that targets the S 1 B receptor which plays an important role in auto mean diseases such as inflammatory bowel disease.
Okay.
Talk to me one point six million Americans currently suffer from IBD and as many as 70,000 new patients are diagnosed in u.s. Annually, we entered into an exclusive licensing agreement with Miss it be she to develop and commercialize him so much in April 2019 and January twenty. We completed an FDA-approved cardiovascular clinical trial protocol that compared to Placebo and moxifloxacin off the primary endpoint demonstrated that MSL mod had no effect on QT interval prolongation and no other secondary safety signals were identified. We expect initiate a multi-armed randomized placebo-controlled phase two study in twenty-twenty and ulcerative colitis for him Selma's on slide Twenty-One. We highlight no vote three which wage recently licensed in for the US and Canada. Nova three is a non-aqueous. I drop for the treatment of dry eye prescription dry and Market represents a great opportunity with 6.8% of the adult table.
projected to have
Diagnose dry eye disease and prevalence will increase with age.
If approved Nova 3 will be the first new prescription treatment for dry eye disease with mechanism of action that is different from currently available products. Its phase two studies already been completed which showed significant and clinically meaningful Improvement in both signs and symptoms of dry eye disease. There's a phase three study underway, and we expect to initiate a second phase three study later this year.
To wrap up on slide twenty-two. We have provided overview of the twenty-twenty vision for Three core businesses which includes both a look back and what has driven performance and look ahead to what is coming into Focus for 20 21st Bausch & Lomb, we expect mid single-digit growth to continue for twenty twenty based on five years of organic Revenue growth for Ultra bio inoculating preservation and new products, like lumify and vice versa looking ahead. We see significant opportunities in the side. He launched in the US and EU and the rest of the world the ramp of our platform and the expected launch of an extended depth of focus for the iol platform.
next
Silence well absorbing the headwinds from a presume blue mats in 2020. Rgi business will be based on two years of high single TRX growth Forsyth Faxon increased market share or trillions and double-digit growth driven by market access for our relistor oral business.
I'm twenty twenty. We are playing forward to also the Glenview ramp-up continued development of new formulations and indications for her fax meant and pipeline expansion including don't walk him a Salman north of dermalogix. We expect this business to return to growth in 2020 based on a 73% organic Revenue growth for the mod franchise weekly walk you over to your ex growth and increased commercial Access Driving improved gross-to-net and the continued ramp of launched products, including Silicon Valley and entry know looking at head we speak with your building out the cash pay model with more products telemedicine in e-commerce and the launch of a slow. Finally we continue to expect to deliver on our three-year cakers on a constant currency basis and from that point of 2019 guidance. We expect Revenue to grow at 4 to 6, % kegger and adjusted ebitda to grow at 5 to 8 % K Ker
with that operator
It's open up the line for questions.
We will now begin the question-and-answer session to ask a question you may have press * then 1 on your touchtone phone. If you are using a speaker phone, please pick up your handset before pressing the keys off all your question, please press * then two at this time. We will pause momentarily to assemble the roster.
The first question today comes from Terrence Flynn of Goldman Sachs, please. Go ahead great. Thanks for taking the questions. Maybe two from me. Just wondering at a high level. What's in bad faith your 2020 guidance for net pricing across the portfolio how that compares to 2019. And then on cyhi, the launch in Japan was wondering any details you can share on Market chef and then how we should think about pricing and positioning as you approach.